SOLA Biosciences
Preclinical-stage biopharmaceutical company developing platform-directed gene therapies that modulate cellular protein quality control to address diseases caused by protein misfolding. The organization operates research and laboratory sites in Greater Boston (USA) and Tokyo (Japan) and advances pipeline gene therapy candidates targeting neurodegenerative indications including ALS, Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease.
Industries
Nr. of Employees
small (1-50)
Patents
Products
SOL-257
Preclinical gene therapy candidate designed to enhance cellular protein-folding machinery to selectively refold or remove misfolded TDP-43 in ALS; configured for single-dose administration in intended therapeutic use.
Pipeline candidates (SOL-175, SOL-368, SOL-410)
Additional pipeline programs described as early-stage programs targeting Huntington’s disease (SOL-175), Parkinson’s disease (SOL-368), and Alzheimer’s disease (SOL-410), developed from the same platform approach.
SOL-257
Preclinical gene therapy candidate designed to enhance cellular protein-folding machinery to selectively refold or remove misfolded TDP-43 in ALS; configured for single-dose administration in intended therapeutic use.
Pipeline candidates (SOL-175, SOL-368, SOL-410)
Additional pipeline programs described as early-stage programs targeting Huntington’s disease (SOL-175), Parkinson’s disease (SOL-368), and Alzheimer’s disease (SOL-410), developed from the same platform approach.
Services
Partnering with foundations and external organizations to advance preclinical efficacy studies and translational research.
Presentation of preclinical data and program updates at scientific conferences and symposia.
Partnering with foundations and external organizations to advance preclinical efficacy studies and translational research.
Presentation of preclinical data and program updates at scientific conferences and symposia.
Expertise Areas
- Gene therapy development
- Protein homeostasis and chaperone engineering
- Preclinical development and in vivo efficacy studies
- Neurodegenerative disease therapeutics (ALS, HD, PD, AD)
Key Technologies
- Gene therapy
- Targeted chaperone / fusion protein engineering
- Protein quality control modulation
- Preclinical animal disease models
News & Updates
Announcement of Series Pre-A+ financing with Curie Bio to accelerate platform and candidate development.
Series Pre-A+ financing completion announcement (additional date listing on site).
Establishment of a Tokyo-based subsidiary and registered office location for Japan operations.
Research grant agreement with the Amyotrophic Lateral Sclerosis Association to advance animal efficacy studies of SOL-257.
Presentation of preclinical proof-of-concept data for the SOL-257 gene therapy program at neuroscience and ALS-focused meetings.
Media coverage reporting that SOL-257 improved motor function and extended survival in two ALS mouse models.
Announcement of Series Pre-A+ financing with Curie Bio to accelerate platform and candidate development.
Series Pre-A+ financing completion announcement (additional date listing on site).
Establishment of a Tokyo-based subsidiary and registered office location for Japan operations.
Research grant agreement with the Amyotrophic Lateral Sclerosis Association to advance animal efficacy studies of SOL-257.
Presentation of preclinical proof-of-concept data for the SOL-257 gene therapy program at neuroscience and ALS-focused meetings.
Media coverage reporting that SOL-257 improved motor function and extended survival in two ALS mouse models.